Evidence map›Paper›PMID 40887896›Full record

ArticleNMR in biomedicine2025

Automatic Identification of Potential Cellular Metabolites for Untargeted NMR Metabolomics.

Jiashang Chen, Angela Rao, Rajshree Ghosh Biswas, Ella J Zhang, Jonathan Xin Zhou, Evan Zhang, Zuzanna Kobus, Marta Kobus, Li Su, David C Christiani and 2 more

Abstract read
In one paragraph

Article in NMR in biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Analysis of serum NMR metabolomics in fibrotic diseases of the myocardium.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiashang ChenDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0003-2596-0243
Angela RaoDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Rajshree Ghosh BiswasDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-9967-6868
Ella J ZhangDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0001-3102-3788
Jonathan Xin ZhouDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Evan ZhangDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Zuzanna KobusDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Marta KobusDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-1290-0626
Li SuDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
David S WishartDepartments of Computing Science and Biological Sciences, University of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0002-3207-2434
Leo L ChengDepartments of Radiology and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5975-5406

Funding

Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuliR01AG070257 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JENKINS, BRUCE G, XIE, ZHONGCONG · 2021 to 2025
$3.9M
Novel metabolomic contrast probes for human lung cancer characterizationR01CA273010 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FARRAR, CHRISTIAN T · 2022 to 2025
$3.3M
CIHR MFE-194064NCI NIH HHS CA273010NCI NIH HHS R01 CA273010NCI NIH HHS R35 CA197449NIA NIH HHS R01 AG070257
6 · The paper itself

Abstract

An organism's metabolic profile provides vital information pertaining to its physiology or pathology. To monitor these biochemical changes, Nuclear Magnetic Resonance (NMR) spectroscopy has found success in non-invasively observing metabolite changes within intact samples in an untargeted manner. However, biological samples are chemically complex, comprised of many different constituents (amino acids, carbohydrates, and lipids) at varying concentrations depending on physiological and pathological conditions. Due to the narrow spectral window of proton NMR, compound resonance frequencies can often overlap, making the identification and monitoring of metabolites difficult and time consuming, particularly when dealing with large numbers of samples. Here, we introduce a Python program (ROIAL-NMR) to systematically identify potential metabolites from defined proton NMR spectral regions-of-interest (ROIs), which are identified from complex biological samples (i.e., human serum, saliva, sweat, urine, CSF, and tissues) using the Human Metabolome Database (HMDB) as a reference platform. Briefly, for disease-versus-control studies, the program considers disease types and utilizes study-defined ROIs together with their differing intensity levels, according to sample types, in differentiating disease from control to propose potential metabolites represented by these ROIs in an output table. In this report, we illustrate the utility of the program with one of our recent studies, where we measured proton NMR spectra of serum samples taken from lung cancer (LC) patients, with and without Alzheimer's disease and related dementia (ADRD). The program successfully identified 88 metabolites, with 66 differentiating LC from control patients, and 80 distinguishing LC patients with ADRD from those without ADRD to provide important information regarding pathophysiology in complex biological samples.

Indexed as

MetabolomeMetabolomicsAutomationHumansMagnetic Resonance Spectroscopyautomated metabolite identificationnuclear magnetic resonance spectroscopypython program

Identifiers

PMID40887896
PMCPMC12445015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.